Efficacy and Biomarker Data From BEYOND: A Randomized Phase 3 Study of First-Line Chemotherapy ± Bevacizumab in Chinese Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer

Efficacy and Biomarker Data From BEYOND: A Randomized Phase 3 Study of First-Line Chemotherapy ± Bevacizumab in Chinese Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer Locally Advanced Non-Small Cell Lung Cancer C. Zhou, Y. Wu, G. Chen, X. Liu, Y. Zhu, S. Lu, J. Feng, J. He, B. Han, J. Wang, G. Jiang, C. Hu, H. Zhang, G. Cheng, X. Song, Y. Lu, H. Pan, W. Zheng, and A. Yin; Shanghai Pulmonary Hospital, Shanghai, China, Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangzhou, China, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China, Academy of Military Medical Sciences Affiliated Hospital (307 Hospital of PLA), Beijing, China, Beijing Chest Hospital, Beijing, China, Shanghai Chest Hospital, Jiao Tong University, Shanghai, China, Jiangsu Cancer Hospital, Shanghai, China, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou, China, Beijing Cancer Hospital, Beijing, China, Fudan University Shanghai Cancer Center, Shanghai, China, The Second Xiangya Hospital of Central South University, Changsha, China, Cancer Hospital of Shantou University Medical College, Shantou, China, Beijing Hospital of Ministry of Health, Beijing, China, Affiliated Cancer Hospital of Guangxi Medical University, Guangxi, China, West China Hospital, Sichuan University, Chendu, China, Sir Run Run Shaw Hospital, Hangzhou, China, Roche (China) Holding Ltd, Shanghai, China